Williams, Gwendolyn
Thyagaraj, Suraj
Fu, Audrey
Oshinski, John
Giese, Daniel
Bunck, Alexander C.
Fornari, Eleonora
Santini, Francesco
Luciano, Mark
Loth, Francis
Martin, Bryn A.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS111283)
National Institute of General Medical Sciences (P20GM1033408, 4U54GM104944-04TBD)
National Center for Advancing Translational Sciences (UL1TR002378)
Article History
Received: 11 November 2020
Accepted: 3 March 2021
First Online: 18 March 2021
Declarations
:
: Not applicable.
: Not applicable.
: BAM is a full-time employee at Alcyone Therapeutics and has received grant support from Genentech, Minnetronix Neuro, Biogen, Voyager Therapeutics, and Alcyone Therapeutics. BAM is scientific advisory board member for Anuncia Inc., Alcyone Therapeutics Inc., International Society for Hydrocephalus and CSF Disorders, and the Chiari and Syringomyelia Foundation and has served as a consultant to Roche, InviCRO, Praxis Medicines, SwanBio Therapeutics, Cerebral Therapeutics, Minnetronix Medical, Genentech and CereVasc. DG is a full-time employee of Siemens Healthcare since December 2018. All of the work related to the current study was performed prior and / or outside of his duties at Siemens.